{"id":50789,"date":"2022-11-14T08:02:28","date_gmt":"2022-11-14T07:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/"},"modified":"2022-11-14T08:02:28","modified_gmt":"2022-11-14T07:02:28","slug":"transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/","title":{"rendered":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022"},"content":{"rendered":"
\n

\nWinning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022\n<\/p>\n

<\/a><\/p>\n

\nReaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I\/IIa trial\n<\/p>\n

STRASBOURG, France–(BUSINESS WIRE)–$TNG<\/a>–Regulatory News:\n<\/p>\n

\nTransgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (\u201cBioInvent\u201d) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced that a paper co-authored by researchers from Transgene and BioInvent is the recipient of this year\u2019s Journal for ImmunoTherapy of Cancer (JITC) \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award. The paper on BT-001 was highlighted at the annual Society for Immunotherapy of Cancer (SITC) conference being held November 8-12, 2022 in Boston, MA.<\/b>\n<\/p>\n

\nThe annual award, judged by a prestigious review committee of SITC leadership and the JITC Editorial Board, recognizes one paper in the \u201cOncolytic and Local Immunotherapy\u201d category for presenting outstanding research on the role of therapeutic agents designed to target tumor cells or the tumor microenvironment.\n<\/p>\n

\nThe winning paper, Vectorized Treg-depleting \u03b1CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject \u2018cold\u2019 tumors<\/i>, demonstrates in vivo<\/i> proof of concept for Treg depleting immune checkpoint blocking vectorized \u03b1CTLA-4 as a highly effective and safe strategy to target CTLA-4.\n<\/p>\n

\nTransgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene\u2019s Invir.IO\u2122 platform that is armed with an anti-CTLA-4 antibody to illicit a strong and effective anti-tumor response. The drug is currently being evaluated in a Phase I\/IIa clinical trial as a single agent and in combination with the PD-1 checkpoint inhibitor KEYTRUDA\u00ae (pembrolizumab) against solid tumors. Positive initial Phase I data announced in June 2022 confirmed the mechanism of action of BT-001 as a single agent and demonstrated first signs of anti-tumor activity.\n<\/p>\n

\nThe papers\u2019 two co-first authors, Dr Monika Semmrich, Principal Scientist at BioInvent, and Dr Jean-Baptiste Marchand, Head of the Protein Science Lab at Transgene, will each receive a monetary prize. The award has been presented at the SITC Meeting Awards Ceremony, taking place Friday, November 11 from 8:00 \u2013 8:20 a.m. EST.\n<\/p>\n

\nThe full paper can be accessed here<\/a>.\n<\/p>\n

\nKEYTRUDA\u00ae is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.<\/i>\n<\/p>\n

\nAbout BT-001<\/i><\/b>\n<\/p>\n

\nBT-001 is an oncolytic virus generated using Transgene\u2019s Invir.IO\u2122 platform and its patented large-capacity VVcop<\/sub>TK–<\/sup>RR–<\/sup> oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA-4 antibody generated by BioInvent\u2019s proprietary n-CoDeR\u00ae<\/sup>\/F.I.R.S.T\u2122 platforms, and the human GM-CSF cytokine. By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response. As a consequence, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA-4 antibody will be greatly improved. BT-001 is being co-developed as part of a 50\/50 collaboration on oncolytic viruses between Transgene and BioInvent. To know more on BT-001, watch our video here<\/a>.\n<\/p>\n

\nAbout Transgene<\/i><\/b>\n<\/p>\n

\nTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.\n<\/p>\n

\nThe Company\u2019s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac<\/i>\u00ae platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO\u2122 platform).\n<\/p>\n

\nWith Transgene\u2019s myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.\n<\/p>\n

\nWith its proprietary platform Invir.IO\u2122, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u2122 collaboration with AstraZeneca.\n<\/p>\n

\nAdditional information about Transgene is available at: www.transgene.fr<\/a>.\n<\/p>\n

\nFollow us on Twitter: @TransgeneSA<\/a>\n<\/p>\n

\nDisclaimer<\/i><\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTransgene:<\/b>
Lucie Larguier<\/b>
Director Corporate Communications & IR
\n
+33 (0)3 88 27 91 04
\n
investorrelations@transgene.fr<\/span><\/a>\n<\/p>\n

\nMedia: MEDiSTRAVA Consulting<\/b>
David Dible\/Sylvie Berrebi\/George Underwood<\/b>
+44 (0)203 928 6900
\n
transgene@medistrava.com<\/span><\/a>\n<\/p>\n

\nBioInvent:<\/i><\/b>
Cecilia Hofvander<\/b>
Senior Director Investor Relations
\n
+46 (0)46 286 85 50
\n
cecilia.hofvander@bioinvent.com<\/span><\/a>\n<\/p>\n

\nBioInvent International AB (publ):<\/b>
Co. Reg. No. Org nr: 556537-7263
\n
Visiting address: Ideongatan 1
\n
Mailing address: 223 70 LUND
\n
Phone: +46 (0)46 286 85 50
\n
www.bioinvent.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I\/IIa trial STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50789","6":"format-standard","7":"category-industry"},"yoast_head":"\nTransgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I\/IIa trial STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T07:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022\",\"datePublished\":\"2022-11-14T07:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/\"},\"wordCount\":972,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005015\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/\",\"name\":\"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005015\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"datePublished\":\"2022-11-14T07:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005015\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221113005015\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/","og_locale":"en_US","og_type":"article","og_title":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend","og_description":"Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I\/IIa trial STRASBOURG, France–(BUSINESS WIRE)–$TNG–Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-14T07:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022","datePublished":"2022-11-14T07:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/"},"wordCount":972,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/","url":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/","name":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg","datePublished":"2022-11-14T07:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221113005015\/en\/1192643\/21\/Logo_Transgene.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-joint-paper-on-bt-001-wins-jitc-best-oncolytic-and-local-immunotherapy-paper-award-for-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transgene and BioInvent Joint Paper on BT-001 Wins JITC \u201cBest Oncolytic and Local Immunotherapy Paper\u201d Award for 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50789"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50789\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}